Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study (DDI-COC)

Open-Label, Fixed-Sequence 3-Period Study to Determine the Effects of Repeated Oral Dosing of AQX-1125 on the Pharamacokinetics, Safety and Tolerability of a Combination Oral Contraceptive in Healthy Female Subjects

This is an open-label, fixed sequence, 4 cycle, drug-drug interaction (DDI) study of AQX-1125 in healthy female subjects on combination oral contraceptives (COC).

Study Overview

• Status: Completed
• Conditions: Healthy Volunteer
• Intervention / Treatment: Drug: AQX-1125; Drug: Combined Oral Contraceptive

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 1

Contacts and Locations

Study Locations

• Netherlands
  • Groningen, Netherlands
    • PRA Health Sciences - Early Development Serices

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Aged 18-45 years, inclusive, at time of signing Informed Consent
• Adult females of child bearing potential, who are non-pregnant and non-lactating, and must agree to use adequate additional contraception from the start of Treatment Period A until 90 days after the last dose of AQX-1125
• BMI 18.0 - 35.0 kg/m2
• Good physical and mental health based on medical history, physical examination, clinical laboratory, ECG and vital signs, as judged by the investigator

Exclusion Criteria:

• Previous participation in the current study
• Any clinically significant history of breakthrough bleeding
• Using tobacco or other nicotine containing products within 12 months prior to the first study-specific COC-cycle intake
• History of alcohol abuse or drug addiction
• Positive drug and alcohol screen at screening and (each) admission to the clinical research center
• Average intake of more than 24 units of alcohol per week
• Positive screen for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibodies or anti-human immunodeficiency virus (HIV) 1 and 2 antibodies
• Participation in a drug study within 30 days prior to screening. Participation in more than 2 other drug studies in the 10 months prior to (the first) drug administration in the current study
• Donation or loss of more than 100 mL of blood within 60 days prior to the start of Treatment Period A, on Day 1. Donation or loss of more than 1.0 liters of blood in the 10 months prior to the start of Treatment Period A, on Day 1
• Significant and/or acute illness within 5 days prior to Day 1 in Treatment Period A, that may impact safety assessments, in the opinion of the investigator
• Unsuitable veins for blood sampling

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Pre-Treatment, Treatment Cycles A & B; Pre-Treatment: Two cycles of a combined oral contraceptive (COC) taken orally once daily for 21 days followed by 7 COC-free days. Treatment Period A: COC containing taken orally once daily for 21 days followed by 7 COC-free days. Treatment Period B: COC taken orally once daily for 21 days, with once daily oral 200 mg AQX-1125 (2 x 100 mg tablets) co-administered from Day 13 to 21, followed by 7 COC-free days

Drug: AQX-1125; Investigational Drug; Drug: Combined Oral Contraceptive; COC containing 100 ug Levonorgestrel (LNG) and 20 ug Ethinyl Estradiol (EE)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum observed plasma concentration (Cmax) of COC taken with AQX-1125	To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC	8 Weeks (from start of treatment period A to completion of treatment period B)
Time to attain maximum observed plasma concentration (tmax) of COC taken with AQX-1125	To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC	8 Weeks (from start of treatment period A to completion of treatment period B)
Area under the plasma concentration-time curve up to 24 hours (AUC0-24) of COC taken with AQX-1125	To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC	8 Weeks (from start of treatment period A to completion of treatment period B)
Terminal elimination rate constant (Kel) of COC taken with AQX-1125	To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC	8 Weeks (from start of treatment period A to completion of treatment period B)
Terminal elimination half-life (t1/2) of COC taken with AQX-1125	To assess the effect of multiple doses of 200 mg AQX-1125 once daily (qd) on the pharmacokinetics (PK) of the COC	8 Weeks (from start of treatment period A to completion of treatment period B)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability of AQX-1125 200 mg qd administered with the COC	Safety and tolerability will be assessed by the severity and frequency of adverse events, which will include any abnormal clinically significant vital signs, laboratory tests, electrocardiogram and physical examination findings	16 weeks (from start of pre-treatment cycle 1 to completion of treatment period B)
Maximum observed plasma concentration (Cmax) of AQX-1125 taken with COC	To assess the PK of 200 mg AQX-1125 qd when given together with the COC	8 Weeks (from start of treatment period A to completion of treatment period B)
Time to attain maximum observed plasma concentration (tmax) of AQX-1125 taken with COC	To assess the PK of 200 mg AQX-1125 qd when given together with the COC	8 Weeks (from start of treatment period A to completion of treatment period B)
Area under the plasma concentration-time curve up to 24 hours (AUC0-24) of AQX-1125 taken with COC	To assess the PK of 200 mg AQX-1125 qd when given together with the COC	8 Weeks (from start of treatment period A to completion of treatment period B)
Terminal elimination rate constant (Kel) of AQX-1125 taken with COC	To assess the PK of 200 mg AQX-1125 qd when given together with the COC	8 Weeks (from start of treatment period A to completion of treatment period B)
Terminal elimination half-life (t1/2) of AQX-1125 taken with COC	To assess the PK of 200 mg AQX-1125 qd when given together with the COC	8 Weeks (from start of treatment period A to completion of treatment period B)

Collaborators and Investigators

• Sponsor: Aquinox Pharmaceuticals (Canada) Inc.

Study record dates

Study Major Dates

• Study Start (Actual): November 22, 2017
• Primary Completion (Actual): March 29, 2018
• Study Completion (Actual): April 5, 2018

Study Registration Dates

• First Submitted: March 19, 2018
• First Submitted That Met QC Criteria: March 23, 2018
• First Posted (Actual): March 27, 2018

Study Record Updates

• Last Update Posted (Actual): June 13, 2018
• Last Update Submitted That Met QC Criteria: June 12, 2018
• Last Verified: June 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Reproductive Control Agents; Contraceptive Agents, Female; Contraceptive Agents; Contraceptives, Oral; Contraceptives, Oral, Combined
• Other Study ID Numbers: AQX-1125-104

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No